Azenta, Inc.
A life sciences company that helps researchers around the world store, manage, and analyze biological samples. Its automated ultra-cold freezers, sample tubes and vials, lab software, and cold-chain logistics keep everything from clinical-trial specimens to blood samples safe, while its GENEWIZ brand provides gene sequencing and DNA synthesis services. Founded in 1978 in Massachusetts as Brooks Automation, it spent decades building robots for making semiconductors before pivoting to biological samples and renaming itself Azenta in late 2021. Fittingly, the same robotics know-how that once handled delicate silicon wafers now gently shuffles frozen vials in automated freezers—an unexpected turn from chips to cells.
Granted 10.7K
Granted 194.3K · Sold 41.4K
Granted 210.5K · Bought 15.0K · Sold 316
Granted 70.1K · Bought 4.3K · Sold 18.3K
Granted 48.2K · Sold 10.9K
Granted 1.9K
Granted 5.5K
Sold 8.3K
Granted 8.1K · Sold 2.4K
Granted 73.7K
Granted 36.8K · Sold 33.1K
Granted 72.0K
Granted 25.7K · Sold 23.3K
Bought 29.5K
Granted 24.3K
Granted 37.1K · Bought 417 · Sold 1.6K
Granted 12.0K
Granted 36.2K · Sold 1.6K
Granted 51.2K · Sold 15.4K
Bought 8.6K
Granted 9.6K · Sold 9.8K
Granted 18.2K · Sold 348
Granted 26.2K · Sold 2.3K
Granted 17.7K
Granted 21.8K
Granted 17.8K
Granted 4.0K · Bought 12.0K
Granted 15.8K
Granted 8.0K · Sold 2.8K
Granted 9.7K
Granted 8.6K · Sold 480
Granted 2.5K · Bought 4.9K
Granted 4.0K · Sold 132
Granted 3.2K
Granted 3.6K
Granted 2.5K · Bought 1.0K
Granted 43 · Sold 191
Granted 2.5K
Granted 1.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Koffey QuentinDirector · 3 transactions | — | 4.62M | 10.7K | — | — |
| Schwartz Stephen SCEO, Director · 10 transactions | +34.2% | 446.5Kas of Nov 2023 | 194.3K | — | 41.4K |
| Marotta JohnPresident and CEO, Director · 10 transactions | — | 213.2K | 210.5K | 15.0K | 316 |
| Robertson Lindon GEVP & Chief Financial Officer · 14 transactions | +6% | 121.1Kas of Nov 2023 | 70.1K | 4.3K | 18.3K |
| Joseph JasonSVP, General Counsel, Secy. · 20 transactions | +40.8% | 112.6Kas of Nov 2024 | 48.2K | — | 10.9K |
| Wrighton Mark SDirector · 1 transaction | +1.7% | 111.8Kas of Feb 2022 | 1.9K | — | — |
| Palepu Krishna G.Director · 2 transactions | +5.5% | 105.4Kas of Feb 2023 | 5.5K | — | — |
| Montone William T.SVP, Human Resources · 2 transactions | -8.3% | 91.9Kas of Sep 2021 | — | — | 8.3K |
| Martin Joseph RDirector · 4 transactions | -0.8% | 85.2Kas of Jun 2023 | 8.1K | — | 2.4K |
| Lin Lawrence Y.EVP, CFO and Treasurer · 7 transactions | — | 79.7K | 73.7K | — | — |
| Gray David CChief Strategy & New Business · 14 transactions | -6.8% | 74.9Kas of Nov 2023 | 36.8K | — | 33.1K |
| Starr EphraimSVP, Gen Counsel & Secretary · 3 transactions | — | 68.4K | 72.0K | — | — |
| Jarzynka DavidPresident, Semi Solutions · 4 transactions | +5.5% | 46.3Kas of Nov 2021 | 25.7K | — | 23.3K |
| Cornog William LDirector · 6 transactions | — | 45.5K | — | 29.5K | — |
| Zane Ellen MDirector · 3 transactions | -24.3% | 41.1Kas of Aug 2023 | 24.3K | — | — |
| Zhou GingerSVP and GM, Multiomics · 17 transactions | — | 38.8K | 37.1K | 417 | 1.6K |
| Davis Robyn CDirector · 4 transactions | +55.7% | 33.6Kas of Feb 2025 | 12.0K | — | — |
| Pirogova OlgaSVP and CHRO · 7 transactions | — | 33.0K | 36.2K | — | 1.6K |
| Vacha RobinSVP, GM Life Science Products · 18 transactions | -18.3% | 31.3Kas of Feb 2024 | 51.2K | — | 15.4K |
| McManus MatthewEVP & Chief Operating Officer · 1 transaction | — | 29.5Kas of Aug 2022 | — | 8.6K | — |
| Pietrantoni DavidPrincipal Accounting Officer · 5 transactions | +2.3% | 28.2Kas of Nov 2021 | 9.6K | — | 9.8K |
| Wang David DongSVP & GM, SMS · 6 transactions | — | 24.0Kas of Dec 2024 | 18.2K | — | 348 |
| Cueto HermanEVP, Chief Financial Officer · 5 transactions | — | 23.9Kas of Nov 2024 | 26.2K | — | 2.3K |
| McLaughlin EricaDirector · 5 transactions | +366.6% | 22.5K | 17.7K | — | — |
| Casal FrankDirector · 6 transactions | — | 21.8K | 21.8K | — | — |
| Martin William E. IIIPresident Multiomics · 1 transaction | — | 17.8K | 17.8K | — | — |
| Malus Alan JDirector · 3 transactions | — | 17.0Kas of May 2025 | 4.0K | 12.0K | — |
| Nova Tina SusanDirector · 4 transactions | — | 15.8K | 15.8K | — | — |
| Rosenblatt MichaelDirector · 4 transactions | +65.5% | 13.0Kas of Feb 2024 | 8.0K | — | 2.8K |
| Doshi DipalDirector · 2 transactions | — | 9.7K | 9.7K | — | — |
| Hughes ViolettaVP, Chief Accounting Officer · 6 transactions | — | 9.6Kas of Feb 2025 | 8.6K | — | 480 |
| Madaus Martin DDirector · 2 transactions | — | 7.4Kas of Nov 2024 | 2.5K | 4.9K | — |
| Crowley KimberlySVP, Chief HR Officer · 7 transactions | +82.1% | 7.4Kas of Jan 2023 | 4.0K | — | 132 |
| Sriram VandanaSVP Finance & Corp. Controller · 4 transactions | — | 6.4Kas of Jan 2023 | 3.2K | — | — |
| Puhy Dorothy EDirector · 1 transaction | — | 3.6Kas of Feb 2023 | 3.6K | — | — |
| Hirsch DidierDirector · 2 transactions | — | 3.5Kas of Nov 2024 | 2.5K | 1.0K | — |
| De Jesus LindaChief Commercial Officer, LS · 2 transactions | +109.4% | 2.8Kas of Jul 2022 | 43 | — | 191 |
| Bousa Edward PeterDirector · 1 transaction | — | 2.5Kas of Feb 2024 | 2.5K | — | — |
| Coyne MitchellSVP and GM, Life Sciences Proj · 1 transaction | — | 1.9Kas of Nov 2022 | 1.9K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -96.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.